| State | Closed |
| Type | Subsidiary |
| Parent Company | Lundbeck |
| HQ | Bothell, WA, US |
| Founded | 2004 |
| Website | alderbio.com |
| Cybersecurity rating | AMore |
Alder BioPharmaceuticals was founded in 2004 and is headquartered in Bothell, WA, US
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Alder BioPharmaceuticals
John Latham
Chief Scientific Officer
Larry Benedict
Vice President, Finance
Mark Litton
Chief Business Officer and Treasurer
Paul Cleveland
Interim President and Chief Executive Officer
Alder BioPharmaceuticals Office Locations
Alder BioPharmaceuticals has an office in Bothell
Bothell, WA, US (HQ)
11804 North Creek Pkwy
Alder BioPharmaceuticals Financials and Metrics
Summary Metrics
Founding Date | 2004 |
Total Funding | $355 m |
Investors | Sevin Rosen Funds, TPG, Redmile Group, Delphi Ventures, Ventures West, WRF Capital, H.I.G. Capital, Novo Ventures |
In total, Alder BioPharmaceuticals had raised $355 m. Alder BioPharmaceuticals is a subsidiary of Lundbeck
Alder BioPharmaceuticals Revenue
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 113.0k | ||||||||||||||||
Cost of goods sold | 113.0k | 683.0k | |||||||||||||||
Gross profit | |||||||||||||||||
General and administrative expense | 3.2m | 2.7m | 3.2m | 3.7m | 3.9m | 4.3m | 6.0m | 6.5m | 6.2m | 10.0m | 9.5m | 8.2m | 11.7m | 12.2m | 10.7m | 44.5m | 21.6m |
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 12.9m | 70.3m | 57.6m | 209.9m | 408.0m | 234.0m | 178.0m | 230.0m | 170.6m | 79.7m | 127.8m | 87.3m | 202.0m | 115.8m | 94.4m | 126.1m | 88.4m |
Accounts Receivable | 91.0k | 57.0k | 81.0k | ||||||||||||||
Prepaid Expenses | 1.3m | 4.1m | 7.1m | 11.3m | 13.7m | 13.6m | 16.6m | 15.8m | 23.7m | 19.8m | 21.2m | 17.6m | 7.3m | 7.6m | 6.6m | 3.8m | 11.0m |
Inventories | 936.0k | 936.0k | 936.0k | 936.0k | 936.0k |
Annual
Quarterly
| USD | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (5.4m) | (12.8m) | 15.9m | (14.7m) | (32.3m) | (59.3m) | (33.4m) | (72.2m) | (107.4m) | (100.3m) | (175.0m) | (234.5m) | (87.0m) | (155.4m) | (216.3m) | (117.9m) | (176.3m) |
Depreciation and Amortization | 188.0k | 355.0k | 527.0k | 195.0k | 385.0k | 571.0k | 235.0k | 505.0k | 1.0m | 747.0k | 1.5m | 2.2m | 801.0k | 1.6m | 2.1m | 533.0k | 1.1m |
Inventories | (936.0k) | (936.0k) | |||||||||||||||
Accounts Payable | (518.0k) | 448.0k | (539.0k) | 305.0k | 443.0k | 5.8m | 4.9m | 2.9m | 968.0k | 10.3m | 9.8m | 12.5m | 5.3m | 8.0m | 8.2m | 6.4m | (1.3m) |
| USD | Q1, 2014 |
|---|---|
Financial Leverage | -0.1 x |
Alder BioPharmaceuticals Cybersecurity Score
Alder BioPharmaceuticals Environment, Social & Governance (ESG) Ratings
Alder BioPharmaceuticals Online and Social Media Presence
195 Twitter followers
Alder BioPharmaceuticals has 195 Twitter Followers. The number of followers has increased 1.4% month over month and increased 16.1% quarter over quarter
Alder BioPharmaceuticals's Trends
Alder BioPharmaceuticals News and Updates
September 17, 2019
Thinking about buying stock in Aclaris Therapeutics, Alder Biopharmaceuticals, Capricor Therapeutics, Canopy Growth, or ConocoPhillips?
NEW YORK, Sept. 17, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACRS, ALDR, CAPR, CGC, and COP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
September 16, 2019
Alder BioPharmaceuticals stock rockets on heavy volume after $1.95 billion buyout deal
Shares of Alder BioPharmaceuticals Inc. blasted 83% higher on very heavy volume in premarket trading Monday, after the developer of migraine treatment eptinezumab agreed to be bought out by Denmark-based H. Lundbeck A/S in a deal valued at $1.95 billion. Trading volume was already more than 4.6 m…
September 16, 2019
Alder (ALDR) Alert: Johnson Fistel Investigates Proposed Sale of Alder BioPharmaceuticals, Inc.; Are Shareholders Getting a Fair Deal?
SAN DIEGO, Sept. 16, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR) ("Alder") breached their fiduciary duties in connection with the proposed sale of the...
March 04, 2019
Alder BioPharmaceuticals, Inc. Announces Closing of Public Offering and Private Placement of Common Stock and Exercise in Full of Option to Purchase Additional Shares
BOTHELL, Wash., March 04, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the closing of its previously announced underwritten public offering of 13…
February 28, 2019
Alder BioPharmaceuticals, Inc. Prices Public Offering of Common Stock
BOTHELL, Wash., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today the pricing of an underwritten public offering of 11,304,348 shares of its …
Alder BioPharmaceuticals Blogs
October 30, 2019
Fundamental Change Company Notice
ALDER BIOPHARMACEUTICALS, INC. FUNDAMENTAL CHANGE COMPANY NOTICE AND OFFER TO REPURCHASE TO THE HOLDERS OF ALDER BIOPHARMACEUTICALS, INC. 2.50% Convertible Senior Notes due 2025 (CUSIP NO. 014339AA3) THE OFFER TO REPURCHASE WILL EXPIRE AT 5:00 P.M., NEW YORK CITY TIME, ON December 11, 2019, UNLESS
October 11, 2019
Lundbeck and Alder BioPharmaceuticals announce updated information in the tender offer materials filed with SEC
Updated tender offer materials provide additional summary information regarding existing Lundbeck offer terms, including existing CVR terms, and additional information regarding existing Alder director and officer share ownership Offer terms remain unchanged from commencement, with Lundbeck
October 10, 2019
Alder BioPharmaceuticals® Announces First-in-Human Dosing in Phase 1 ALD1910 Study for Preventive Treatment of Migraine
ALD1910 is Alder’s first clinical candidate designed to inhibit pituitary adenylate cyclase-activating polypeptide (PACAP), a novel target in treating migraine BOTHELL, Wash. , Oct. 10, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on
August 28, 2019
Alder BioPharmaceuticals® to Present at Two Upcoming September Investor Conferences
BOTHELL, Wash. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that members of the management team will provide a business overview and
August 06, 2019
Alder BioPharmaceuticals® Reports Second Quarter 2019 Financial and Operating Results
Data presented at American Academy of Neurology and American Headache Society Annual Meetings continue to support eptinezumab’s differentiated clinical profile and impact on quality of life measures Core commercial leadership team secured, including field payer team, in anticipation of expected
August 02, 2019
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Content Import
Fri, 08/02/2019 - 16:01
Alder BioPharmaceuticals® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 2, 2019 at 4:01 PM EDT
This release …
Alder BioPharmaceuticals Frequently Asked Questions
When was Alder BioPharmaceuticals founded?
Alder BioPharmaceuticals was founded in 2004.
Who are Alder BioPharmaceuticals key executives?
Alder BioPharmaceuticals's key executives are John Latham, Larry Benedict and Mark Litton.
How many employees does Alder BioPharmaceuticals have?
Alder BioPharmaceuticals has 202 employees.
Who are Alder BioPharmaceuticals competitors?
Competitors of Alder BioPharmaceuticals include Bencard Allergie, Chiesi Pharmaceutical and KLAB.
Where is Alder BioPharmaceuticals headquarters?
Alder BioPharmaceuticals headquarters is located at 11804 North Creek Pkwy, Bothell.
Where are Alder BioPharmaceuticals offices?
Alder BioPharmaceuticals has an office in Bothell.
How many offices does Alder BioPharmaceuticals have?
Alder BioPharmaceuticals has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies